SECONDARY MYELOFIBROSIS
Clinical trials for SECONDARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for SECONDARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to boost stem cell transplant success in aggressive blood cancers
Disease control Recruiting nowThis study tests a two-step approach for people with advanced myeloproliferative neoplasms (blood cancers). First, patients receive a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) to reduce cancer cells. Then, they undergo a donor…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 02:15 UTC
-
New combo therapy aims to make bone marrow transplants safer for older blood cancer patients
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to standard transplant care can prevent a serious side effect called graft-versus-host disease (GVHD) in older adults with myelofibrosis or related blood cancers. About 50 participants will receive ruxolitinib before, during, a…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:14 UTC
-
New combo aims to tame transplant complications in bone marrow cancer
Disease control Recruiting nowThis study is for people with myelofibrosis, a type of bone marrow cancer. It tests giving a JAK inhibitor drug before, during, and after a stem cell transplant from a half-matched donor. The goal is to reduce a serious side effect called graft-versus-host disease without raising…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New drug cocktail aims to halt deadly blood cancer progression
Disease control Recruiting nowThis study tests whether adding iadademstat to standard ASTX727 therapy improves outcomes for people with advanced myeloproliferative neoplasms (MPNs), a group of blood cancers. About 62 adults with accelerated or blast-phase MPNs will be randomly assigned to receive ASTX727 alon…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New study aims to map Real-World care for rare bone marrow disease
Knowledge-focused Recruiting nowThis study is a registry that will follow about 200 people in Germany who have myelofibrosis (a rare bone marrow disorder) and anemia. It does not test a new treatment but instead collects information on which therapies patients receive, how their blood counts and spleen size res…
Matched conditions: SECONDARY MYELOFIBROSIS
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated May 17, 2026 02:00 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: SECONDARY MYELOFIBROSIS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC